Alkeon Capital Management
CRBU icon

Alkeon Capital Management’s Caribou Biosciences CRBU Stock Holding History

Alkeon Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,743,505
Closed -$14.1M – 103
2024
Q1 		$14.1M Sell
2,743,505
-370,059
-12% -$2.28M 0.02% 89
2023
Q4 		$17.8M Buy
3,113,564
+1,468,701
+89% +$7.26M 0.04% 85
2023
Q3 		$7.86M Buy
1,644,863
+287,800
+21% +$1.79M 0.01% 96
2023
Q2 		$5.77M Buy
1,357,063
+302,418
+29% +$1.36M 0.01% 110
2023
Q1 		$5.6M Sell
1,054,645
-3,958
-0.4% -$24.7K 0.01% 119
2022
Q4 		$6.65M Sell
1,058,603
-163,488
-13% -$1.45M 0.03% 119
2022
Q3 		$12.9M Buy
1,222,091
+348,542
+40% +$3.25M 0.04% 118
2022
Q2 		$4.74M Sell
873,549
-350,000
-29% -$2.68M 0.01% 134
2022
Q1 		$11.2M Sell
1,223,549
-23,076
-2% -$243K 0.02% 131
2021
Q4 		$18.8M Hold
1,246,625
– – 0.03% 127
2021
Q3 		$29.8M Buy
+1,246,625
New +$30.5M 0.05% 126

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alkeon Capital Management's CRBU Position: Q2 2024 in Review

Alkeon Capital Management sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 2,743,505 shares — an estimated $14.1M sold.

Alkeon Capital Management first reported a position in CRBU in Q3 2021 and held it in 11 quarters. The position peaked at $29.8M in Q3 2021. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

  • Alkeon Capital Management reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
  • Alkeon Capital Management sold 2,743,505 Caribou Biosciences shares in Q2 2024, an estimated $14.1M.
  • Alkeon Capital Management first reported a position in Caribou Biosciences in Q3 2021 and held it in 11 quarters.
  • Alkeon Capital Management's Caribou Biosciences position peaked at $29.8M in Q3 2021.
  • 140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Alkeon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.